Bevacizumab toxicity in heavily pre-treated recurrent epithelial ovarian cancer

被引：0
|
作者：
Martin, I. [1 ]
Urban, R. [1 ]
Goff, B. [1 ]
机构：
[1] Univ Washington, Med Ctr, Seattle, WA 98195 USA
来源：
GYNECOLOGIC ONCOLOGY | 2015年 / 139卷 / 01期
关键词：
D O I：
10.1016/j.ygyno.2015.07.065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：197 / 197
页数：1
相关论文
共 50 条
  • [21] Feasibility of using pemetrexed as a salvage regimen in heavily pre-treated patients with ovarian cancer: A retrospective review
    Dottino, Peter
    Dashkoff, Matthew
    Beddoe, Ann Marie
    INDIAN JOURNAL OF CANCER, 2020, 57 (04) : 491 - 493
  • [22] The usefulness of bevacizumab for relief from symptomatic malignant ascites in patients with heavily treated recurrent ovarian cancer
    Shimizu, Yusuke
    Kajiyama, Hiroaki
    Yoshida, Kosuke
    Tamauchi, Satoshi
    Nakanishi, Toru
    Kikkawa, Fumitaka
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2019, 45 (12) : 2435 - 2439
  • [23] Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer
    Sharma, R.
    Graham, J.
    Mitchell, H.
    Brooks, A.
    Blagden, S.
    Gabra, H.
    BRITISH JOURNAL OF CANCER, 2009, 100 (05) : 707 - 712
  • [24] Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma
    Sharma, S
    Neale, MH
    Di Nicolantonio, F
    Knight, LA
    Whitehouse, PA
    Mercer, SJ
    Higgins, BR
    Lamont, A
    Osborne, R
    Hindley, AC
    Kurbacher, CM
    Cree, IA
    BMC CANCER, 2003, 3 (1)
  • [25] Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer
    R Sharma
    J Graham
    H Mitchell
    A Brooks
    S Blagden
    H Gabra
    British Journal of Cancer, 2009, 100 : 707 - 712
  • [26] Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma
    Sanjay Sharma
    Michael H Neale
    Federica Di Nicolantonio
    Louise A Knight
    Pauline A Whitehouse
    Stuart J Mercer
    Bernard R Higgins
    Alan Lamont
    Richard Osborne
    Andrew C Hindley
    Christian M Kurbacher
    Ian A Cree
    BMC Cancer, 3
  • [27] Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
    Chura, Justin C.
    Van Iseghem, Kelin
    Downs, Levi S., Jr.
    Carson, Linda F.
    Judson, Patricia L.
    GYNECOLOGIC ONCOLOGY, 2007, 107 (02) : 326 - 330
  • [28] Bevacizumab plus irinotecan therapy in relapsed, heavily pre-treated malignant glioma: A case series
    Friedland, D. M.
    Ali, S. A.
    Ahmad, A.
    Rahman, M.
    Bejjani, G.
    Braffet, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Weekly Paclitaxel plus Bevacizumab in Heavily Pre-Treated Non-Small-Cell Lung Cancer (NSCLC) Patients
    Cardona, Andres F.
    Rojas, Leonardo
    Carranza, Hernan
    Vargas, Carlos A.
    Otero, Jorge M.
    Cuello, Mauricio
    Corrales, Luis
    Martin, Claudio
    Arrieta Rodriguez, Oscar
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S655 - S655
  • [30] Electrochemotherapy with intravenous bleomycin for heavily pre-treated vulvar cancer patients
    Perrone, Anna Myriam
    Corrado, Giacomo
    Coada, Camelia Alexandra
    Garganese, Giorgia
    Fragomeni, Simona Maria
    Tagliaferri, Luca
    Di Costanzo, Stella
    De Crescenzo, Eugenia
    Morganti, Alessio Giuseppe
    Ferioli, Martina
    De Terlizzi, Francesca
    Scambia, Giovanni
    De Iaco, Pierandrea
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (04) : 473 - 481
12345